Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Mithril Capital Management

Investor type Venture Capital
Founders Ajay Gopal Royan Peter Thiel

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 64
Average round size
info
The average size of a deal this fund participated in
$83M
Portfolio companies 33
Rounds per year 6.40
Lead investments 16
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.48
Exits 6
Key employees 6
Stages of investment
Late Stage Venture
Seed

Areas of investment

  • Health Care
  • Enterprise Software
  • Medical Device
  • Software
  • Financial Services
Summary

Mithril Capital Management is the famous VC, which was founded in 2012. The main department of described VC is located in the San Francisco. The venture was found in North America in United States.

The top activity for fund was in 2014. Deals in the range of 50 - 100 millions dollars are the general things for fund. Comparing to the other companies, this Mithril Capital Management performs on 20 percentage points less the average number of lead investments. The top amount of exits for fund were in 2019. The typical startup value when the investment from Mithril Capital Management is more than 1 billion dollars. Considering the real fund results, this VC is 27 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 deals per year.

The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Biotechnology, SaaS. Among the most popular portfolio startups of the fund, we may highlight Palantir Technologies, Auris Health, Inc., AppDirect.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Mithril Capital Management, startups are often financed by Desmarais Group, Accel, iNovia Capital. The meaningful sponsors for the fund in investment in the same round are Lux Capital, Bessemer Venture Partners, Union Square Ventures. In the next rounds fund is usually obtained by Bessemer Venture Partners, Temasek Holdings, Union Square Ventures.

This organization was formed by Ajay Gopal Royan, Peter Thiel. Besides them, we counted 6 critical employees of this fund in our database.

Read more

Funds with similar focus

Funds from United States
Funds with similar focus located in United States:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
AAS Technologies Hackensack, New Jersey, United States
Bladex Panamá, Panama, Panama City
CDP Capital Technology Ventures Canada, Montréal, Quebec
Chivas Venture England, London, United Kingdom
Early Stage Enterprises New Jersey, Princeton, United States
hiCenter Ventures Hefa, Hefa, Israel
J.P. Morgan Cazenove England, London, United Kingdom
LAF China, Guangdong, Shantou
Mannai Corporation Ad Dawhah, Doha, Qatar
Ningbo Puhui Qiye Guanli China, Ningbo, Zhejiang
P1 Ventures -
Pontos Group Finland, Helsinki, Southern Finland
RATP Group France, Ile-de-France, Paris
Skylake Capital -
Social Impact Capital New York, New York, United States
Sony Music Entertainment Japan Chiyoda, Japan
Sunsea China, Guangdong, Shenzhen
T Investment -
Techstars Autonomous Technology Boston, Massachusetts, United States
The Ballast Fund Colorado, Edwards, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Neocis

Dental
Health Care
Medical Device
Robotics
$40M27 Oct 2022 Miami, Florida, United States

Genetesis

Artificial Intelligence
Emergency Medicine
Health Diagnostics
Machine Learning
Medical Device
$17M06 Oct 2022 Ohio, United States

OnJuno

Banking
Financial Services
FinTech
$18M01 Oct 2022 Bengaluru, Karnataka, India

Fractyl Laboratories

Biotechnology
Health Care
Medical Device
Wellness
15 Aug 2022 Massachusetts, United States

ForSight Robotics

Health Care
Medical
Medical Device
Robotics
$55M18 Jul 2022 Israel, North District, Israel

Oma Fertility

Fertility
Health Care
Wellness
$29M21 Jun 2022 Santa Barbara, California, United States

GreyOrange

Hardware
Industrial Automation
Logistics
Robotics
Software
$110M17 May 2022 Singapore, Central, Singapore

Ankyra

Biotechnology
$45M12 Nov 2021 Boston, Massachusetts, United States

Helion Energy

Energy
Environmental Engineering
Renewable Energy
$500M05 Nov 2021 Washington, United States
News
Paxos raises $300 million to build a cryptocurrency infrastructure giant

– Paxos has raised $300m funding.
– The round was led by Oak HC/FT and joined by Declaration Partners, PayPal Ventures, Mithril Capital, Senator Investment Group, Liberty City Ventures and WestCap.
– Paxos offers different products, such as crypto trading and settlement, custody and the ability to issue tokens.
– It focuses on big enterprise clients, such as Revolut, Crédit Suisse, Société Générale and StoneX.
– The company tries to be as compliant as possible. And it plans to remain committed to regulation across several geographies and verticals.

Adagio Therapeutics Announces $336 Million Series C Financing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19

– Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today announced the completion of a $336m Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor.
– Existing investors Fidelity Management & Research Company, LLC, OrbiMed, Polaris Partners, Mithril, GV, Population Health Partners, Adimab and Omega Funds also participated in the financing.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Mithril Capital Management?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: